Multicentre development and validation of a risk model integrating immunotherapy and coagulation biomarkers for thrombosis in autoimmune neurological disorders
International Immunopharmacology · 2026
DOI: 10.1016/j.intimp.2026.116402 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Suhong Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang Province, 325035, China; Department of Pharmacy, The Second Affiliat…. Hauptthemen laut MEDLINE: Thrombosis, Autoimmune Diseases, Nervous System Diseases, Immunotherapy. Die Arbeit nennt 50 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Patients with Autoimmune Neurological Disorders (ANDs) require routine immunomodulatory therapy, which inherently increases thrombosis risk. Despite this recognised association, reliable tools for thrombosis prediction remain limited, highlighting the need for accurate risk stratification to inform targeted prevention strategies. PATIENTS AND METHODS: This multicentre retrospective study developed a machine learning-based thrombosis risk prediction model using data from 786 patients with ANDs receiving immunomodulatory therapy. The model was trained on data from three centres and externally validated on an independent fourth centre, evaluating six algorithms based on the area under the receiver operating characteristic curve (AUROC), area under the precision-recall curve (AUPRC), and Brier score. Feature selection and Shapley Additive Explanations (SHAP) analysis were applied to ensure model interpretability. RESULTS: Among all algorithms tested, XGBoost (XGB) demonstrated the best performance. On the external validation set, the XGB model achieved an AUROC of 0.949, AUPRC of 0.544, and Brier score of 0.045, significantly outperforming the traditional Padua score. SHAP analysis identified the top three thrombotic risk factors: elevated D-dimer levels, prolonged immobilisation, and advanced age. The total doses of intravenous immunoglobulin and glucocorticoid were also confirmed as significant contributors. The model further enabled stratification into low-, intermediate-, and high-risk groups, offering a practical tool for individualised thromboprophylaxis. CONCLUSION: This study presents a high-performing, interpretable model for early thrombosis risk prediction in patients with ANDs, which facilitates timely clinical decision-making and targeted preventive strategies to reduce thromboembolic complications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang Province, 325035, China; Department of Pharmacy, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang…
- Department of Pharmacy, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310009, China.
- Department of Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310003, China. Electronic address: ziqiye@zju.edu.cn.
- Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, Zhejiang Province, 324000, China. Electronic address: 454299018@wmu.edu.cn.
- Department of Pharmacy, Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, Zhejiang Province, 310016, China. Electronic address: 3413120@zju.edu.cn.
- Department of Pharmacy, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310009, China. Electronic address: lingyanyu@zju.edu.cn.
Zitieren
APA
Wang, S., Hu, W., Ye, Z., Xu, J., Hu, J., Lou, G., Yu, L., Hu, Y., Mao, F., Chen, S., Chen, J., & Dai, H. (2026). Multicentre development and validation of a risk model integrating immunotherapy and coagulation biomarkers for thrombosis in autoimmune neurological disorders. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2026.116402
Vancouver
Wang S, Hu W, Ye Z, Xu J, Hu J, Lou G, et al. Multicentre development and validation of a risk model integrating immunotherapy and coagulation biomarkers for thrombosis in autoimmune neurological disorders. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2026.116402
BibTeX
@article{Wang2026,
author = {Wang, Suhong and Hu, Wei and Ye, Ziqi and Xu, JiZhuang and Hu, Jie and Lou, Guodong and Yu, Lingyan and Hu, Yani and Mao, Fengqian and Chen, Shunan and Chen, Jie and Dai, Haibin},
title = {Multicentre development and validation of a risk model integrating immunotherapy and coagulation biomarkers for thrombosis in autoimmune neurological disorders},
journal = {International Immunopharmacology},
year = {2026},
doi = {10.1016/j.intimp.2026.116402}
}
EUVIMED